|Tildacerfont||Adult Classic Congenital Adrenal Hyperplasia||Topline results from CAHmelia-203 in the second half of 2023. Topline results from CAHmelia-204 in the second half of 2024.||CAHmelia Studies|
|Pediatric Classic Congenital Adrenal Hyperplasia||Topline data in adolescents in the second half of 2023||CAHptain Studies|
|Polycystic Ovary Syndrome||Topline results in the first half of 2023||P.O.W.E.R. Study|
Tildacerfont is a CRF1 receptor antagonist designed to potentially offer markedly improved disease control and reduced steroid burden in patients with classic congenital adrenal hyperplasia (CAH) and other diseases characterized by elevated levels of adrenocorticotropic hormone (ACTH). Tildacerfont binds to CRF1 receptors on the pituitary gland, inhibiting excessive production of ACTH, and ultimately limiting the production of adrenal androgens such as androstenedione, a precursor to testosterone.